UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European journal of cancer (1990), 2018-04, Vol.93, p.19-27

2018

Volltextzugriff (PDF)

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

European journal of surgical oncology, 2011-10, Vol.37 (10), p.890-896

2011

Volltextzugriff (PDF)

Diagnostic yield and safety of endoscopic ultrasound-guided trucut [corrected] biopsy in patients with gastric submucosal tumors: a prospective study

Endoscopy, 2009-04, Vol.41 (4), p.329-334

2009

Volltextzugriff (PDF)

Primary angiosarcoma of the breast-series of 11 consecutive cases-a single-centre experience

Current oncology (Toronto), 2018-02, Vol.25 (1), p.e50-53

2018

Volltextzugriff (PDF)

HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch

Annals of oncology, 2018-10, Vol.29, p.viii5-viii5

2018

Volltextzugriff (PDF)

The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC

Annals of oncology, 2018-10, Vol.29, p.viii672-viii672

2018

Volltextzugriff (PDF)

Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis

Annals of oncology, 2018-10, Vol.29, p.viii103-viii103

2018

Volltextzugriff (PDF)

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level

British journal of dermatology (1951), 2008-09, Vol.159 (3), p.597-605

2008

Volltextzugriff (PDF)

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

ESMO open, 2024-09, Vol.9 (9), p.103697, Article 103697

2024

Volltextzugriff (PDF)

The analysis of the outcomes and factors related to iliac–obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases

European journal of surgical oncology, 2013-03, Vol.39 (3), p.304-310

2013

Volltextzugriff (PDF)

Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection

Journal of the European Academy of Dermatology and Venereology, 2011-03, Vol.25 (3), p.264-270

2011

Volltextzugriff (PDF)

Cetuximab and panitumumab in elderly patients with metastatic colorectal cancer

Journal of geriatric oncology, 2014-10, Vol.5, p.S39-S39

2014

Volltextzugriff (PDF)

In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection

European journal of cancer (1990), 2006, Vol.42 (2), p.159-164

2006

Volltextzugriff (PDF)

Lymph node status and survival in cutaneous malignant melanoma—sentinel lymph node biopsy impact

European journal of surgical oncology, 2003-09, Vol.29 (7), p.611-618

2003

Volltextzugriff (PDF)

Retrospective study comparing tolerability of trastuzumab as adjuvant setting in two groups of early breast cancer patients: ≥ 70 years vs < 70 years

Journal of geriatric oncology, 2014-10, Vol.5, p.S31-S31

2014

Volltextzugriff (PDF)

74P Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy

Annals of oncology, 2020-05, Vol.31, p.S40-S40

2020

Volltextzugriff (PDF)

260P Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer

Annals of oncology, 2024-09, Vol.35, p.S324-S324

2024

Volltextzugriff (PDF)

252P Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy

Annals of oncology, 2024-09, Vol.35, p.S320-S321

2024

Volltextzugriff (PDF)

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib

European journal of surgical oncology, 2009-01, Vol.35 (1), p.87-91

2009

Volltextzugriff (PDF)

Does Z0011 trial changed our clinical practice in patients with metastases in sentinel lymph node (SNB)

Annals of oncology, 2017-05, Vol.28, p.i6

2017

Volltextzugriff (PDF)

Diagnostic yield and safety of endoscopic-ultrasound guided trucut biopsy in patients with gastric submucosal tumors: a prospective study

Endoscopy, 2009-06, Vol.41 (6), p.503-503

2009

Volltextzugriff (PDF)

VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

Annals of oncology, 2023-10, Vol.34 (10), p.951-953

2023

Volltextzugriff (PDF)

Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Journal of clinical oncology, 2024-06, Vol.42 (18), p.2149

2024

Volltextzugriff (PDF)

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Annals of oncology, 2022-05, Vol.33, p.S199-S199

2022

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(79)
Tagungsberichte
(1)

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(22)
Journal Of Clinical Oncology
(16)
Breast
(6)
European Journal Of Surgical Oncology
(4)
Melanoma Research
(4)
Annals Of Surgical Oncology
(3)
Journal Of Geriatric Oncology
(3)
Cancer Research
(2)
Endoscopy
(2)
Esmo Open
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

Diagnostic yield and safety of endoscopic ultrasound-guided trucut [corrected] biopsy in patients with gastric submucosal tumors: a prospective study

Primary angiosarcoma of the breast-series of 11 consecutive cases-a single-centre experience

HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch

The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC

Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

The analysis of the outcomes and factors related to iliac–obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases

Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection

Cetuximab and panitumumab in elderly patients with metastatic colorectal cancer

In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection

Lymph node status and survival in cutaneous malignant melanoma—sentinel lymph node biopsy impact

Retrospective study comparing tolerability of trastuzumab as adjuvant setting in two groups of early breast cancer patients: ≥ 70 years vs < 70 years

74P Clinical value of HER3/ErbB3 serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy

260P Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer

252P Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib

Does Z0011 trial changed our clinical practice in patients with metastases in sentinel lymph node (SNB)

Diagnostic yield and safety of endoscopic-ultrasound guided trucut biopsy in patients with gastric submucosal tumors: a prospective study

VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Suchergebnisse filtern